Wednesday, January 22, 2025 NCI Precision Medicine TrialsNewer approaches employing combinations of targeted therapy, or targeted therapy with standard therapies, need to be considered. The NCI embarked on three second-generation precision medicine trials to address this need: ComboMATCH, iMATCH, and myeloMATCH. The design of these trials and necessary infrastructure are discussed in the following perspective.Harris LN, Blanke CD, Erba HP, Ford JM, Gray RJ, LeBlanc ML, Hu-Lieskovan S, Litzow MR, Luger SM, Meric-Bernstam F, O'Dwyer PJ, Othus MKD, Politi K, Shepherd LE, Allegra CJ, Chen HX, Ivy SP, Korde LA, Little RF, McShane LM, Moscow JA, Patton DR, Thurin M, Yee LM, Doroshow JH. The New NCI Precision Medicine Trials. Clinical Cancer Research 29: 4728-4732. 2023. https://doi.org/10.1158/1078-0432.CCR-23-0917
